|Bid||0.00000 x 0|
|Ask||0.00000 x 0|
|Day's Range||0.73820 - 0.76990|
|52 Week Range||0.43500 - 1.41000|
|Beta (3Y Monthly)||-0.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs.
Tetra Bio-Pharma Inc., ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), today announced it has entered into a non-binding proposal (the "Proposal") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction"). Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain.
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii. The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001. This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain. It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia.
ORLEANS, Ontario, Oct. 24, 2018 -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the.
ORLEANS, ON , Oct. 16, 2018 /CNW/ - October 17 th, 2018 will be remembered as one of the most significant dates in Canadian history, in our lifetime. While there will continue to be arguments on both sides of the debate, the Government of Canada has legislated that adults will have access to cannabis for recreational use, subject to a set of guidelines that will vary from province to province. Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), is a Canadian company that is a global leader in the discovery and development of cannabis and cannabinoid-based pharmaceuticals and is the only company in North America to work with both Health Canada and the U.S. Food and Drug Administration on clinical programs to produce the rigorous scientific evidence required by these regulators as well as by medical professionals and insurance companies.
Media Advisory - Dr. Chamberland, Expert Spokesperson available to discuss legalization of recreational cannabis
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years' experience in the development of new drugs in the North American pharmaceutical industry. Since joining Tetra Bio-Pharma in June 2016, Dr. Chamberland and his team have accomplished numerous milestones.
The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002. The FDA also provided feedback on the chemistry and manufacturing aspects of the drug development plan. The FDA further confirmed that the product control strategy, ensuring the identity, potency, purity and quality of the PPP002 buccal tablets was acceptable thereby determining that Tetra Bio-Pharma’s plan is on track for drug approval. "We have now completed our meetings with the U.S. FDA and Tetra is well on its way to finalizing the development plan to bring PPP002 to market,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford’s manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford’s to conduct the fabrication, packaging and labeling of PPP001.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™ mucoadhesive product, PPP002. The FDA confirmed the eligibility of the 505(b)(2) regulatory pathway for the product PPP002 and that the efficacy and systemic safety would be supported by the corporation’s proposed comparative bioavailability study and if successful Tetra could apply for FDA approval in Q1 2019, for Chemotherapy Induced Nausea and Vomiting as well as Anorexia associated with Weight Loss in Patients with AIDS. "We are very pleased with the outcome of yesterday’s meeting with the U.S. FDA,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma.
ORLEANS, Ontario, Sept. 24, 2018-- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development, has made significant progress in its clinical trial for PPP005 the cannabis oil-based ...
TORONTO, Sept. 20, 2018-- North Bud Farms Inc., is pleased to announce the closing of a non-brokered private placement offering consisting of 3,778,000 units, at a price of $0.25 per Unit, for gross proceeds ...
This clinical data and vapor compound identification will allow Tetra to bridge to its existing and future clinical data of the Phase 3. The bridge will provide a significantly reduced time to market and reduced development cost for the commercialization of PPP001 as a treatment for fibromyalgia.
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on Thursday, September 20, 2018 under the stock symbol “NBUD”. “We are proud to achieve this milestone in advance of the historic legalization of Cannabis in Canada on October 17, 2018 and less than 10 months since the Company’s inception which is a testament to the dedication and execution of our experienced management team,” said Ryan Brown, Founder and CEO of North Bud Farms. Each such option entitles the holder to acquire one common share for a period of 5 years at an exercise price of $0.25 per common share.
ORLEANS, Ontario, Sept. 13, 2018-- Tetra Bio-Pharma Inc., a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device ...
ORLEANS, Ontario, Sept. 11, 2018-- Tetra Bio-Pharma Inc., a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing ...
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that its board of directors has declared a dividend-in-kind (the “Dividend”) of 15,500,000 common shares (each a "North Bud Share") of North Bud Farms Inc. ("North Bud") owned by Tetra pro rata to the holders of record of outstanding common shares (each, a "Tetra Share") of Tetra (the "Shareholders of Record") as at September 7, 2018 (the “Dividend Record Date”). The Dividend will be payable on September 12, 2018.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant. “I am very excited to have the opportunity of contributing my pharmaceutical marketing knowledge within the growing cannabinoid-based products sector,” said Steeve Neron.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), today announced the submission of multiple applications for Orphan Drug Designation for cannabinoids to the U.S. Food and Drug Administration, for the treatment of various forms of rare cancers and ocular diseases. The applications align with Tetra’s strategy to develop cannabis prescription drug products for the treatment of several rare cancers and to expand its market exclusivity in the treatment of ocular diseases.